Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2017

Published: Mar, 2017 | Pages: 136 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2017, provides an overview of the Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline landscape.

Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes and balance problems. Risk factors include longer duration of therapy, pre-existing neuropathy and type of chemotherapeutic agent.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 1, 23, 2 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Chemotherapy Induced Peripheral Neuropathy - Overview 8
Chemotherapy Induced Peripheral Neuropathy - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 13
Products under Development by Companies 14
Products under Development by Universities/Institutes 16
Chemotherapy Induced Peripheral Neuropathy - Therapeutics Assessment 17
Assessment by Target 17
Assessment by Mechanism of Action 20
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Chemotherapy Induced Peripheral Neuropathy - Companies Involved in Therapeutics Development 27
Achelios Therapeutics Inc 27
Advinus Therapeutics Ltd 27
Apollo Endosurgery Inc 28
Aptinyx Inc 28
Asahi Kasei Pharma Corp 29
Can-Fite BioPharma Ltd 29
Celgene Corp 30
DermaXon LLC 30
Eisai Co Ltd 31
Immune Pharmaceuticals Inc 31
INSYS Therapeutics Inc 32
Kineta Inc 32
KPI Therapeutics Inc 33
Krenitsky Pharmaceuticals Inc 33
MAKScientific LLC 34
Metys Pharmaceuticals AG 34
Midatech Pharma US Inc 35
Mundipharma International Ltd 35
Nemus Bioscience Inc 36
Neurocentrx Pharma Ltd 36
Panacea Pharmaceuticals Inc 37
PeriphaGen Inc 37
PharmatrophiX Inc 38
PledPharma AB 38
Sova Pharmaceuticals Inc 39
Virobay Inc 39
WEX Pharmaceuticals Inc 40
Chemotherapy Induced Peripheral Neuropathy - Drug Profiles 41
(amitriptyline + ketamine hydrochloride) - Drug Profile 41
ACY-1083 - Drug Profile 45
AM-1710 - Drug Profile 46
APX-2009 - Drug Profile 48
APX-3330 - Drug Profile 49
BR-297 - Drug Profile 52
cannabidiol - Drug Profile 53
dimiracetam - Drug Profile 56
Drugs for Peripheral Neuropathy - Drug Profile 58
DX-0332 - Drug Profile 59
E-2072 - Drug Profile 60
HM-01 - Drug Profile 61
KCP-400 - Drug Profile 62
ketoprofen - Drug Profile 63
KP-544 - Drug Profile 64
KRN-5500 - Drug Profile 65
LM-11A31BHS - Drug Profile 69
Lpathomab - Drug Profile 71
MR-309 - Drug Profile 74
NB-2111 - Drug Profile 76
NRX-2922 - Drug Profile 77
NT-24336 - Drug Profile 78
PAN-811 - Drug Profile 79
PGN-503 - Drug Profile 81
piclidenoson - Drug Profile 82
pirenzepine hydrochloride - Drug Profile 92
PP-095 - Drug Profile 93
Q-201 - Drug Profile 97
ricolinostat - Drug Profile 98
Small Molecule to Inhibit Cystathionine Gamma Lyase for Inflammatory Pain and Chemotherapy Induced Peripheral Neuropathy - Drug Profile 106
Small Molecule to Inhibit FAAH for Chemotherapy Induced Peripheral Neuropathy - Drug Profile 107
Small Molecules for Pain - Drug Profile 108
Small Molecules to Agonize Adenosine A3 Receptor for Chemotherapy Induced Peripheral Neuropathy - Drug Profile 109
Small Molecules to Block Nav 1.8 for Chemotherapy Induced Peripheral Neuropathy - Drug Profile 110
Small Molecules to Inhibit Hsp90 for Peripheral Neuropathy and Neurodegenerative Disorders - Drug Profile 111
Tetrodotoxin - Drug Profile 112
thrombomodulin alfa - Drug Profile 114
U-2902 - Drug Profile 116
VBY-036 - Drug Profile 118
XEN-106 - Drug Profile 120
XT-150 - Drug Profile 121
Chemotherapy Induced Peripheral Neuropathy - Dormant Projects 122
Chemotherapy Induced Peripheral Neuropathy - Discontinued Products 124
Chemotherapy Induced Peripheral Neuropathy - Product Development Milestones 125
Featured News & Press Releases 125
Appendix 132
Methodology 132
Coverage 132
Secondary Research 132
Primary Research 132
Expert Panel Validation 132
Contact Us 132
Disclaimer 133

List of Tables

Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Achelios Therapeutics Inc, H1 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Advinus Therapeutics Ltd, H1 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Apollo Endosurgery Inc, H1 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Aptinyx Inc, H1 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Asahi Kasei Pharma Corp, H1 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Can-Fite BioPharma Ltd, H1 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Celgene Corp, H1 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by DermaXon LLC, H1 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Eisai Co Ltd, H1 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Immune Pharmaceuticals Inc, H1 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by INSYS Therapeutics Inc, H1 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Kineta Inc, H1 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by KPI Therapeutics Inc, H1 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Krenitsky Pharmaceuticals Inc, H1 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by MAKScientific LLC, H1 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Metys Pharmaceuticals AG, H1 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Midatech Pharma US Inc, H1 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Mundipharma International Ltd, H1 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Nemus Bioscience Inc, H1 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Neurocentrx Pharma Ltd, H1 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Panacea Pharmaceuticals Inc, H1 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by PeriphaGen Inc, H1 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by PharmatrophiX Inc, H1 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by PledPharma AB, H1 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Sova Pharmaceuticals Inc, H1 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by Virobay Inc, H1 2017
Chemotherapy Induced Peripheral Neuropathy - Pipeline by WEX Pharmaceuticals Inc, H1 2017
Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H1 2017
Chemotherapy Induced Peripheral Neuropathy - Discontinued Products, H1 2017